PAIN
Volume 151, Issue 3 , Pages 617-624 , December 2010

A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain

  • Russell K. Portenoy

      Affiliations

    • Beth Israel Medical Center, New York, NY, USA
    • Corresponding Author InformationCorresponding author. Address: Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, First Avenue at 16th Street, New York, NY 10003, USA. Tel.: +1 (212) 844 1505; fax: +1 (212) 844 1503.
    • ,
  • Allen W. Burton

      Affiliations

    • The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Nashat Gabrail

      Affiliations

    • Gabrail Cancer Center, Canton, OH, USA
    • ,
  • Donald Taylor

      Affiliations

    • Georgia Center for Cancer Pain Management & Palliative Medicine, Marietta, GA, USA
    • ,
  • on behalf of the Fentanyl Pectin Nasal Spray 043 Study Group

Received 20 November 2009 ,Revised 26 July 2010 ,Accepted 27 July 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0304-3959(10)00450-1

doi: 10.1016/j.pain.2010.07.028

PAIN
Volume 151, Issue 3 , Pages 617-624 , December 2010

Article Tools

* Image Usage & Resolution